Vor Bio to Participate in the 46th Annual TD Cowen Health Care Conference
Vor Bio (Nasdaq: VOR) will present and hold 1x1 investor meetings at the 46th Annual TD Cowen Health Care Conference in Boston.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Vor Bio (Nasdaq: VOR) will present and hold 1x1 investor meetings at the 46th Annual TD Cowen Health Care Conference in Boston.
The company presentation is scheduled for Monday, March 2, 2026, 9:50–10:20 AM ET. A live webcast and archived replay will be available for 90 days on the company website.
Details
News Market Reaction – VOR
On Feb 23, the day this news came out, VOR closed 13.80% above the previous close.
Data tracked by StockTitan Argus for the Feb 23 session.
Key Figures
- Conference edition
- 46th Annual TD Cowen Health Care Conference
- Event Vor Bio plans to attend
- Presentation date
- March 2, 2026
- Scheduled TD Cowen conference presentation
- Presentation time
- 9:50am–10:20am ET
- Vor Bio conference presentation window
- Webcast availability
- 90 days
- Duration replay will remain available on company website
Historical Context
-
Announced presentation and 1x1 meetings at J.P. Morgan healthcare conference.
-
Added two investor-affiliated directors following a $150M PIPE financing.
-
Announced $150M private placement to fund telitacicept Phase 3 programs.
-
Reported Q3 2025 results with strong efficacy but very large net loss.
-
Priced $100M common stock offering under existing shelf registration.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
1x1 investor meetings financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will be presenting and hosting 1x1 investor meetings at the 46th Annual TD Cowen Health Care Conference in Boston, MA.
Presentation: Monday, March 2, 2026 at 9:50am – 10:20 am ET
Location: Regis
A live webcast and archived replay of the presentation will be remain available for a period of 90 days on the Company’s website at: https://ir.vorbio.com/events-presentations/
About Vor Bio
Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com.
Media & Investor Contacts:
Carl Mauch
cmauch@vorbio.com
Sarah Spencer
investors@vorbio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.